Table 3 Pre-operative and followed-up oncological characteristics of 44 study patients
Completely intrafascial group | Conventional interfascial group | P value | |
|---|---|---|---|
No. clinical T stage (%) | 0.735 | ||
T1 | 3 (15.0) | 3 (12.5) | |
T2 | 12 (60.0) | 17 (70.8) | |
T3 | 5 (25.0) | 4 (16.7) | |
No. clinical N stage (%) | 0.261 | ||
N0 | 16 (80.0) | 22 (91.7) | |
N+ | 4 (20.0) | 2 (8.3) | |
No. pathological T stage (%) | 0.785 | ||
T0 | 1 (5.0) | 2 (8.3) | |
Ta/Tis | 0 (0) | 0 (0) | |
T1 | 1 (5.0) | 0 (0) | |
T2 | 7 (35.0) | 9 (37.5) | |
T3 | 8 (40.0) | 8 (33.3) | |
T4 | 3 (15.0) | 5 (20.8) | |
No. pathological N stage (%) | 0.813 | ||
N0 | 14 (70.0) | 16 (66.7) | |
N1 | 6 (30.0) | 8 (33.3) | |
No. positive surgical margins (%) | 5 (25.0) | 3 (12.5) | 0.284 |
No. incidental prostate cancer (%) | 2 (10.0) | 1 (4.2) | 0.445 |
No. local recurrence (%) | 2 (10.0) | 3 (12.5) | 0.795 |
No. metastatic disease (%) | 2 (10.0) | 7 (29.2) | 0.117 |